

An Independent Licensee of the Blue Cross and Blue Shield Association.

# Breast Surgery and Breast Prosthesis Corporate Medical Policy

File Name: Breast Surgery File Code: 7.01.VT22 Origination: 2016 Last Review: 08/2024 Next Review: 08/2025 Effective Date: 10/01/2024

#### **Description/Summary**

This policy focuses on breast-related procedures that include mastectomy for cancer, prophylactic mastectomy, reconstruction, the management of breast implants, breast reductions, corrections for certain asymmetries. BCBSVT covers medically necessary procedures related to physiological dysfunction, such as breast cancer, congenital and developmental disorders, infection, trauma, surgical complications and macromastia causing physiological dysfunction in men and women. BCBSVT considers procedures that are only performed to reshape normal structures of the body in order to improve one's appearance or self-esteem only, to be **cosmetic and therefore non-covered as benefit exclusions**.

## Policy

Coding Information Click the links below for attachments, coding tables & instructions. Attachment I - CPT<sup>®</sup>/HCPCS Coding Table

Requests for breast surgery should be accompanied by the following documentation:

- The name and date of the proposed surgery
- Date of accident or injury, if applicable
- History of present illness and/or conditions including diagnoses
- Documentation of diagnosis, functional impairment, pain or significant anatomic variance
- How the treatment can be reasonably expected to improve the functional impairment
- If applicable, the description of and CPT<sup>®</sup> coding for planned staged procedure following acute repair, within two years of previous stage or initial primary repair
- Any additional information listed for a specific procedure as indicated for the specific procedures listed below

BCBSVT will review procedures intended to correct complications from a cosmetic procedure, whether the original procedure was medically necessary or a non-covered service. In order for these corrections to be considered medically necessary the subsequent surgery needs to be reconstructive in nature (i.e. procedures performed on abnormal structures of the body, caused by congenital defects, developmental abnormalities, trauma, infection, tumors or disease. It is generally performed to improve function but may also be done to approximate normal appearance).

The procedures in this medical policy are considered **medically necessary** in accordance with the Women's Health and Cancer Rights Act of 1998, when performed as a breast reconstruction procedure following or in connection with mastectomy, breast conservation therapy (BCT) or other diagnostic procedures causing deformity of the breast, in connection with breast cancer, evaluation of breast cancer or suspected breast cancer, to prevent development of breast cancer in high risk patients, reconstruction following breast tissue destruction due to accidental injury, trauma, infection or disease (including other cancers).

For services related to gender affirming surgeries refer to the BCBSVT Gender Affirming Services (Trans Services) Corporate Medical Policy.

# **Policy Guidelines**

Breast Prosthetics (HCPCS codes, L8020\*, L8030\*, L8031\*, L8032\*, L8033\*, L8039, L8499, L8699)

- Breast prosthetics are considered **medically necessary** for the following indications:
  - A diagnosis of breast cancer or a history of breast cancer
  - Following a mastectomy for cancer
  - Following a prophylactic mastectomy
  - For absence of the breast due to trauma, disease or infection
  - A diagnosis of Poland's syndrome
- Breast prosthetics are considered **cosmetic and therefore not covered as a benefit exclusion** when:
  - None of the above indications are met.
  - Obtained only to improve appearance or to improve one's self-esteem.

\*When billed with a diagnosis of breast cancer prior approval is **not** required.

**Mastectomy for Gynecomastia (CPT<sup>®</sup> code 19300)** - surgery due to development of abnormally large mammary gland in biologically male individuals.

- Mastectomy for gynecomastia is considered **medically necessary** for the following:
  - With a diagnosis of breast cancer; **OR**
  - When the criteria for a Prophylactic Mastectomy are met; OR
  - When **ALL** of the following are met:
    - Documented symptoms, including pain or tenderness directly related to the breast tissue, and which has a clinically significant impact upon normal

activities of daily living despite non-narcotic analgesics and antiinflammatory agents; **AND** 

- Appropriate diagnostic evaluation has been done for possible underlying etiology; AND
- $\circ~$  The tissue removed must be glandular breast tissue; AND
- The extra tissue must not be the result of obesity, adolescence, or reversible effects of drug treatment that can be discontinued (this includes drug-induced gynecomastia remaining unresolved six months after cessation of the causative drug therapy); AND
- Additionally, for those under 18 years of age, the following must be submitted as evidence of puberty completion:
  - Documented tanner stage IV or V for members aged 15-18; AND
  - Stable height measurements for 6 months; OR
  - Puberty completion as shown on wrist radiograph.
- Mastectomy for gynecomastia is considered **not medically necessary** when any of the following is present:
  - Conservative attempts to control the pain or tenderness, such as nonnarcotic analgesics and anti-inflammatory agents, have not been attempted.
  - Use of a medication known to cause gynecomastia has not been discontinued.
- Mastectomy for gynecomastia is considered **cosmetic and therefore not covered as a benefit exclusion** for the following circumstances (not an allinclusive list):
  - The tissue being removed is not glandular in nature; **OR**
  - The medically necessary criteria above is not met and the procedure is intended only to improve appearance or to improve one's emotional wellbeing.

**Risk-Reducing (Prophylactic) Mastectomy (CPT<sup>®</sup> code 19303)** - Surgical removal of breasts to reduce the risk of breast cancer occurrence. It is strongly recommended that all candidates for prophylactic mastectomy undergo counseling regarding cancer risks from a health professional skilled in assessing cancer risk other than the operating surgeon and discussion of the various treatment options, including increased surveillance or chemoprevention with the appropriate medication.

- Risk-reducing (prophylactic) mastectomy is considered **medically necessary** for any of the following:
  - A known BRCA1 or BRCA2 mutation; OR
  - At high risk of BRCA1 or BRCA2 mutation due to a known presence of the mutation in relatives; OR
  - Another gene mutation associated with increased risk (eg, PTEN, TP53, CDH1, STK11 or PALB2); OR
  - Li-Fraumeni syndrome, Cowden syndrome or Bannayan-Riley-Ruvalcaba syndrome or a first-degree relative with one of these syndromes; **OR**
  - Lobular carcinoma in situ; OR

- Inflammatory breast cancer; **OR**
- History of radiotherapy to the chest between 10 and 30 years of age; OR
- Such extensive mammographic abnormalities that make biopsy or excision impossible; **OR**
- High risk of breast high risk (defined as lifetime risk of ≥20% of developing breast cancer) as identified by validated models that are largely defined by family history. One such example is the NIH National Cancer Institute Breast Cancer Risk Assessment Tool available at <u>https://bcrisktool.cancer.gov/calculator.html</u>
- Risk-reducing (prophylactic) mastectomy is considered **investigational** for all other indications, including, but not limited to contralateral prophylactic mastectomy in women with breast cancer who do not meet criteria as defined above.

Breast Reconstruction (CPT<sup>®</sup> codes 15771, 15772, 15777, 19340\*, 19342\*, 19350\*, 19357\*, 19361\*, 19364\*, ,19367\*, 19368\*, 19369\*, 19380\*). Utilization of natural or artificial tissue to reconstruct breasts following mastectomy, breast conservation therapy, burns, trauma and diagnostic deformity.

- Breast Reconstruction is considered **medically necessary** for any of the following:
  - For the affected breast
    - When breast tissue is affected by disease, trauma, burns or infection; **OR**
    - When performed in connection with cancer, the evaluation of cancer, the evaluation of suspected cancer (i.e. following biopsy or lumpectomy), or the prevention of breast cancer development in high risk patients; **OR**
    - For prostheses and physical complications of all stages of mastectomy, breast conservation therapy (BCT) or other diagnostic procedures causing deformity (i.e. following biopsy or lumpectomy) including lymphedema treatment. Complication includes, but is not limited to abdominal scar revision/release related to prior tissue needed for breast reconstruction; OR
    - Following the removal of a ruptured silicone gel-filled implant
  - For the unaffected breast
    - o in order to create a symmetrical appearance

\*When billed with a diagnosis of breast cancer, following an approved mastectomy, prior approval is **not** required.

 Breast reconstruction following mastectomy for gynecomastia is considered cosmetic and therefore not covered as a benefit exclusion.

NOTE:

- Use of allogeneic acellular dermal matrix products including AlloDerm®, AlloMend®, Cortiva®, AlloMax™, DermACELL™, DermaMatrix™, FlexHD®, FlexHD®, Pliable™, Graftjacket® may be considered medically necessary when utilized as part of a medically necessary breast reconstruction approved per criteria above.
- Breast reconstruction utilizing autologous fat grafting as part of repair that meets **medical necessity** criteria above may be considered medically necessary and **requires prior approval.**
- The use of adipose-derived stem cells in autologous fat grafting to the breast is considered **investigational**.

- If the above criteria for Breast Reconstruction are not met, the following procedures are considered **cosmetic and therefore not covered as a benefit exclusion:** 
  - Mastopexy (CPT® 19316)
  - Inverted nipple correction (CPT® 19355)
  - Implant repositioning
  - Tattooing of the nipple and/or areola (CPT® Codes 11921, 11922)

**Reduction Mammoplasty (CPT<sup>®</sup> code 19318\***) - Surgical reduction of breasts in women due to size and persistent symptoms. May also be reported for breast surgery related to breast cancer treatment.

- Reduction Mammoplasty is considered **medically necessary** for the treatment of symptomatic macromastia for the following:
  - Breast size/cup has been stable for at least six consecutive calendar months prior to surgery; AND
  - The preoperative evaluation by the surgeon concludes that the amount of breast tissue removed will lead to reasonable prognosis of symptomatic relief; **AND**
  - Presence of one of more of the following:
    - Persistent well-documented symptoms which impair function, interfere with activities of daily or, interfere with sleep. Such symptoms may include headache, pain at neck, shoulder, or back, are attributable to macromastia and there has been at least 3 months of one or more adequate conservative treatments. Such conservative treatments may include special support bras, NSAIDS, muscle relaxants, chiropractic care, and physical therapy; OR
    - Persistent or recurrent sub-mammary intertrigo or tissue ulceration attributable to macromastia that is unresponsive to adequate conservative treatment; OR
    - Thoracic outlet syndrome attributable to macromastia that has not been responsive to 3 months of adequate conservative treatments.
  - Additionally, for those under 18 years of age, the following must be submitted as evidence of puberty completion:
    - Documented tanner stage IV or V for members aged 15-18; AND
    - Stable height measurements for 6 months; OR
    - Puberty completion as shown on wrist radiograph.

NOTE: Medical records from the treating physician or other treating providers must be submitted to outline medical necessity criteria above.

- Reduction Mammaplasty is considered **medically necessary** for breast tissue rearrangement, at the time of or following lumpectomy or partial mastectomy for treatment of breast cancer.
- Reduction Mammoplasty is considered **cosmetic and therefore not covered as a benefit exclusion** for any of the following:
  - Performed in order to improve athletic performance
  - Obtained only to improve appearance or to improve one's self-esteem

• Reduction Mammoplasty is considered **investigational** for all other indications not outlined above.

Removal of implant(s) (CPT<sup>®</sup> codes 19328, 19330); insertion of implant(s) (CPT<sup>®</sup> codes 19340\*, 19342\*, C1789\*); Periprosthetic capsulotomy or capsulectomy (CPT<sup>®</sup> codes 19370, 19371) - The surgical removal of breast implants

- Removal of a silicone gel-filled breast implant may be considered **medically necessary** for any of the following indications:
  - A documented implant rupture; **OR**
  - In cases of infection; OR
  - Extrusion of implant through the skin; **OR**
  - Baker Class III Contracture. NOTE, this only applies to implants originally placed for reconstructive purposes; **OR**
  - Baker Class IV contracture; **OR**
  - $\circ$  Surgical treatment of cancer in the affected breast; **OR**
  - As part of a covered reconstructive surgery for the opposite breast
- Removal of a saline-filled breast implant may be considered **medical necessary** for any of the following indications:
  - A documented implant rupture. NOTE: this only applies to implants originally placed for reconstructive purposes; **OR**
  - Extrusion of implant through the skin; **OR**
  - Baker Class IV Contracture; **OR**
  - Surgical Treatment of cancer in the affected breast; OR
  - $\circ$  As part of a covered reconstructive surgery for the opposite breast
- The following is considered **not medically necessary:** 
  - Removal of an implant when the original reconstruction was for cosmetic reasons and the medical necessity criteria above are not met.
  - Removal of an implant when member has systemic symptoms attributed to connective tissue disease, autoimmune disease, etc.
  - Removal of an implant with Baker Class III Contracture or lower for cosmetic indications
  - Removal of ruptured saline implants for cosmetic indications
  - Removal of implants due to pain not related to contracture or rupture.
- The following is considered **cosmetic and therefore not covered as a benefit exclusion**:
  - Removal of implant only to approve appearance or to improve one's self-esteem

Additional Documentation Required:

- Date of implantation and type of implant
- Objective evidence of leakage

Page **6** of **16** Medical Policy Number: 7.01.VT22 - Baker Contracture Class

|            | Baker Classification of breast contractures:                            |
|------------|---|
| Class I:   | Augmented breast feels as soft as a normal breast                       |
| Class II:  | Breast is less soft and the implant can be palpated but is not visible. |
| Class III: | Breast is firm, palpable and the implant (or its distortion) is visible |
| Class IV:  | Breast is hard, painful, cold, tender and distorted                     |

Unilateral Breast Surgery for Asymmetry: Reduction Mammoplasty (CPT<sup>®</sup> 15771, 15772 & 19318) and/or Augmentation Mammoplasty (CPT<sup>®</sup> code 19325)

- surgical reconstruction in females of one breast by either reducing or enlarging.

- Unilateral Breast Surgery for Asymmetry, Reduction Mammoplasty and/or Augmentation Mammoplasty is considered **medically necessary** for any of the following indications:
  - Biological females must be at least 15 years of age and have reached puberty (criteria below), and have a diagnosis of Poland's syndrome (congenital absence of breasts); **OR**
  - A disfiguring traumatic accident (e.g. burn) or complication of medical treatment (e.g. necrosis); OR
  - A breast infection resulting indisfigurement; AND
  - Additionally, for those under 18 years of age, the following must be submitted as evidence of puberty completion:
    - Documented tanner stage IV or V for members aged 15-18; AND
    - Stable height measurements for 6 months; OR
    - Puberty completion as shown on wrist radiograph.

Additional Documentation Required:

- History and physical findings
- Height and weight
- Size of each breast
- Date of previous surgery, if applicable
- Pathologic diagnosis, if applicable
- Estimate of amount of tissue to be removed in a reduction or size of implant for augmentation.
- The following is considered **cosmetic and therefore not covered as a benefit exclusion**:
  - Unilateral augmentation or reduction mammoplasty intended to create symmetry between otherwise normal breasts and the medically necessary criteria above is not met
  - Unilateral augmentation or reduction mammoplasty intended only to improve appearance or to improve a one's self-esteem

Tattooing of the nipple and/or areola (CPT<sup>®</sup> codes 11920\*, 11921\*, 11922\*) -

Tattoo application as part of Breast Reconstruction.

Tattooing of the nipple and/or areola is considered **medically necessary** when above criteria for Breast Reconstruction are met.

NOTE: Services may be provided by qualified providers or by licensed tattoo artists contracting with a qualified provider, however billing for services must be submitted by the qualified provider contracting with BCBSVT.

#### Tattoo Removal of the radiation oncology tattoo

 It is considered medically necessary to remove the radiation oncology tattoo when the tattoo was placed for purposes of treatment of breast cancer

#### **Reference Resources**

- 1. Blue Cross and Blue Shield Association. Medical Policy Reference Manual 7.01.13 Surgical Treatment of Bilateral Gynecomastia. Last reviewed: 3/2024. Accessed 8/2024.
- 2. Blue Cross and Blue Shield Association. Medical Policy Reference Manual 7.01.153 Adipose-Derived Stem Cells in Autologous Fat Grafting to the Breast. Last reviewed: 2/2024. Accessed 8/2024.
- 3. Blue Cross and Blue Shield Association. Medical Policy Reference Manual 7.01.09 Risk-Reducing Mastectomy. Last reviewed: 8/2023. Accessed 8/2024.
- 4. Blue Cross and Blue Shield Association. Medical Policy Reference Manual 7.01.21 Reduction Mastectomy for Breast-Related Symptoms. Last reviewed: 3/2024. Accessed 8/2024.
- Blue Cross and Blue Shield Association. Medical Policy Reference Manual 7.01.113 - Bioengineered Skin and Soft Tissue Substitutes. Last reviewed: 5/2024. Accessed 8/2024.
- 6. Cuhaci, N., Polat, S.B., Evranos, B., Esroy, R. and Cakir, B. Gynecomastia: clinical evaluation and management. Indian Journal of Endocrinology and Metabolism. 2014 Mar- Apr; 18(2): 150-158.
- Kerrigan, C.L., Collins, E.D., Kim, H.M., Schnurr, P.L., Cunningham, B. and Lowery, J. Reduction mammoplasty: defining medical necessity. Medical Decision Making. 2002 May- Jun; 22(3): 208-17.
- Wolfswinkel, B.S., Lemaine, V., Weathers, W. M., Chike-Obi, C.J, Xue, A.S. and Heller, L. Hyperplastic Breast Anomalies in the Female Adolescent Breast. Seminars in Plastic Surgery. 2013 Feb; 49-55.
- 9. UpToDate Complications of reconstructive and aesthetic breast surgery. Literature review current through 10/2021. Accessed 1/2023.
- 10. UpToDate Overview of Breast Reduction. Literature review current through 12/2022. Accessed 1/2023.

#### **Related Policies**

BCBSVT Medical Policy on Transgender Services BCBSVT Medical Policy on Bioengineered Skin and Soft Tissue Substitutes

#### **Document Precedence**

Blue Cross and Blue Shield of Vermont (BCBSVT) Medical Policies are developed to provide clinical guidance and are based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. The applicable group/individual contract and member certificate language, or employer's benefit plan if an ASO group, determines benefits that are in effect at the time of service. Since medical practices and knowledge are constantly evolving, BCBSVT reserves the right to review and revise its medical policies periodically. To the extent that there may be any conflict between medical policy and contract/employer benefit plan language, the member's contract/employer benefit plan language takes precedence

#### Audit Information

BCBSVT reserves the right to conduct audits on any provider and/or facility to ensure compliance with the guidelines stated in the medical policy. If an audit identifies instances of non-compliance with this medical policy, BCBSVT reserves the right to recoup all non-compliant payments.

### Administrative and Contractual Guidance

#### **Benefit Determination Guidance**

Prior approval may be required and benefits are subject to all terms, limitations and conditions of the subscriber contract.

Incomplete authorization requests may result in a delay of decision pending submission of missing information. To be considered compete, see policy guidelines above.

NEHP/ABNE members may have different benefits for services listed in this policy. To confirm benefits, please contact the customer service department at the member's health plan.

Coverage varies according to the member's group or individual contract. Not all groups are required to follow the Vermont legislative mandates. Member Contract language takes precedence over medical policy when there is a conflict.

If the member receives benefits through an Administrative Services Only (ASO) group, benefits may vary or not apply. To verify benefit information, please refer to the member's employer benefit plan documents or contact the customer service department. Language in the employer benefit plan documents takes precedence over medical policy when there is a conflict.

# Policy Implementation/Update information

| 08/2016 | New policy.  |
|---------|--|
| 12/2016 | Added CPT® Code 20926 for clarification in medical policy.   |
|         | Reviewed and voted at HPC 08/07/2017 with the following:   |
| 08/2017 | Updated related policies section, removed language under prophylactic mastectomy section, added CPT <sup>®</sup> code 15777 as medically necessary, removed language under breast reconstruction added additional medical criteria under breast reconstruction, added coding table to align with codes contained within the medical policy, removed language under removal of implants, removed language under unilateral breast surgery for asymmetry.  |
| 07/2018 | Added CPT <sup>®</sup> code 15777 to require PA  |
| 11/2018 | Added HCPCS code C1789 & Q4122, to require prior authorization. HCPCS codes L2999, L3999, L5999 & L7499 removed from body of policy. Added related policy section.   |
| 11/2019 | References Reviewed. Language regarding tattooing added. Adaptive<br>Maintenance Changes Effective 01/01/2020: Removed codes 19304, 20926<br>codes were deleted. Added codes 15769, 15771, 15772, 15773, 15774,<br>21601, 21602, 21603 to require PA effective 01/01/2020. Updated codes<br>11920, 11921, 11922 as prior approval required unless with a billed with a<br>diagnosis of breast cancer. Added code L8033 to coding table the code is<br>currently on prior approval list. No changes to policy statements. |
| 06/2020 | Clarification of autologous fat grafting and adipose-derived stem cells in autologous fat grafting in breast reconstruction. No other change to policy statement.  |
| 01/2021 | Adaptive Maintenance Updates: Deleted codes 19324 & 19366 effective 01/01/2021. Codes revised effective 01/01/2021 per AM cycle: 19318, 19325, 19328, 19330, 19342, 19357, 19361, 19364, 19367, 19368, 19369, 19370, 19371, 19380.   |
| 03/2021 | Name change from Breast Surgery to Breast Surgery and Breast Prosthesis.<br>Addition of L8032 & L8033. Listed prosthetics codes to not require PA if<br>billed with a diagnosis of breast cancer.  |
| 04/2021 | External input from network provider. Addition of medical necessity<br>indication of breast tissue rearrangement, at the time of or following<br>lumpectomy or partial mastectomy, for CPT 19318 (Reduction<br>Mammoplasty.) No PA needed if billed with a diagnosis of breast cancer.   |
| 07/2021 | Clarifying language added for ruptured silicone breast implants. Also,<br>language added for use of allogeneic acellular dermal matrix products.<br>Added section for Tattoo Removal for Radiation and Oncology as medically<br>necessary. Reference updated.  |
| 03/2022 | Policy Reviewed. References updated. Clarification to breast reduction<br>criteria to include conservative treatment duration of 3 months.<br>Clarification of risk-reducing mastectomy section. Formatting and minor<br>language changes. Removed codes 19301, 19302 & 19303 from requiring<br>prior approval.  |

| 03/2023 | Policy Reviewed. Policy Statements unchanged. Minor formatting changes. References updated.   |
|---------|---|
| 08/2024 | Policy reviewed. Addition of indications for risk-reducing mastectomy.<br>Minor formatting changes for clarity and consistency. References updated. |

### Eligible providers

Qualified healthcare professionals practicing within the scope of their license(s).

### Approved by BCBSVT Medical Directors

Tom Weigel, MD, MBA Vice President and Chief Medical Officer

Tammaji P. Kulkarni, MD Senior Medical Director

## Attachment I CPT<sup>®</sup>/HCPCS Coding Table

| Code<br>Type | Number    | Brief Description  | Policy Instructions   |
|--------------|-----------|--|---|
|              | The follo | wing codes will be considered as me<br>when applicable criteria have bee   |   |
| CPT®         | 11920     | Tattooing, intradermal<br>introduction of insoluble opaque<br>pigments to correct color defects<br>of skin, including<br>micropigmentation; 6.0 sq cm or<br>less | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT®         | 11921     | Tattooing, intradermal<br>introduction of insoluble opaque<br>pigments to correct color defects<br>of skin, including<br>micropigmentation; 6.1 to 20.0 sq<br>cm | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |

| Code<br>Type     | Number | Brief Description   | Policy Instructions   |
|------------------|--------|---|---|
| CPT®             | 11922  | Tattooing, intradermal<br>introduction of insoluble opaque<br>pigments to correct color defects<br>of skin, including<br>micropigmentation; each<br>additional 20.0 sq cm, or part<br>thereof (List separately in<br>addition to code for primary<br>procedure)             | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT®             | 15769  | Grafting of autologous soft tissue,<br>other, harvested by direct excision<br>(eg, fat, dermis, fascia)   | Prior Approval Required   |
| CPT®             | 15771  | Grafting of autologous fat<br>harvested by liposuction technique<br>to trunk, breasts, scalp, arms,<br>and/or legs; 50 cc or less injectate   | Prior Approval Required   |
| CPT <sup>®</sup> | 15772  | Grafting of autologous fat<br>harvested by liposuction technique<br>to trunk, breasts, scalp, arms,<br>and/or legs; each additional 50 cc<br>injectate, or part thereof (List<br>separately in addition to code for<br>primary procedure)                                   | Prior Approval Required   |
| CPT®             | 15773  | Grafting of autologous fat<br>harvested by liposuction technique<br>to face, eyelids, mouth, neck,<br>ears, orbits, genitalia, hands,<br>and/or feet; 25 cc or less injectate   | Prior Approval Required   |
| CPT®             | 15774  | Grafting of autologous fat<br>harvested by liposuction technique<br>to face, eyelids, mouth, neck,<br>ears, orbits, genitalia, hands,<br>and/or feet; each additional 25 cc<br>injectate, or part thereof (List<br>separately in addition to code for<br>primary procedure) | Prior Approval Required   |
| CPT®             | 15777  | Implantation of biologic implant<br>(eg, acellular dermal matrix) for<br>soft tissue reinforcement (ie,<br>breast, trunk) (List separately in<br>addition to code for primary<br>procedure)   | Prior Approval Required   |
| CPT®             | 19300  | Mastectomy for gynecomastia   | Prior Approval Required   |

| Code<br>Type     | Number | Brief Description   | Policy Instructions   |
|------------------|--------|---|---|
| CPT®             | 19301  | Mastectomy, partial (eg,<br>lumpectomy, tylectomy,<br>quadrantectomy, segmentectomy)                                      | No Prior Approval Required  |
| CPT®             | 19302  | Mastectomy, partial (eg,<br>lumpectomy, tylectomy,<br>quadrantectomy,<br>segmentectomy); with axillary<br>lymphadenectomy | No Prior Approval Required  |
| CPT®             | 19303  | Mastectomy, simple, complete  | No Prior Approval Required  |
| CPT®             | 19316  | Mastopexy   | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT®             | 19318  | Breast reduction  | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT®             | 19325  | Breast augmentation with implant  | Prior Approval Required   |
| CPT®             | 19328  | Removal of intact breast implant  | Prior Approval Required   |
| CPT®             | 19330  | Removal of ruptured breast<br>implant, including implant<br>contents (eg, saline, silicone gel)                           | Prior Approval Required   |
| CPT <sup>®</sup> | 19340  | Insertion of breast implant on same day of mastectomy (ie, immediate)   | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT®             | 19342  | Insertion or replacement of breast<br>implant on separate day from<br>mastectomy  | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT <sup>®</sup> | 19350  | Nipple/areola reconstruction  | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT®             | 19355  | Correction of inverted nipples  | Prior Approval Required   |
| CPT®             | 19357  | Tissue expander placement in breast reconstruction, including subsequent expansion(s)                                     | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT®             | 19361  | Breast reconstruction; with latissimus dorsi flap   | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT®             | 19364  | Breast reconstruction; with free<br>flap (eg, fTRAM, DIEP, SIEA, GAP<br>flap)   | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |

| Code<br>Type     | Number | Brief Description  | Policy Instructions   |
|------------------|--------|--|---|
| CPT®             | 19367  | Breast reconstruction; with<br>single-pedicled transverse rectus<br>abdominis myocutaneous (TRAM)<br>flap  | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT®             | 19368  | Breast reconstruction; with single-<br>pedicled transverse rectus<br>abdominis myocutaneous (TRAM)<br>flap, requiring separate<br>microvascular anastomosis<br>(supercharging)   | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT®             | 19369  | Breast reconstruction; with<br>bipedicled transverse rectus<br>abdominis myocutaneous (TRAM)<br>flap   | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT®             | 19370  | Revision of peri-implant capsule,<br>breast, including capsulotomy,<br>capsulorrhaphy, and/or partial<br>capsulectomy  | Prior Approval Required   |
| CPT®             | 19371  | Peri-implant capsulectomy, breast,<br>complete, including removal of all<br>intracapsular contents   | Prior Approval Required   |
| CPT <sup>®</sup> | 19380  | Revision of reconstructed breast<br>(eg, significant removal of tissue,<br>re-advancement and/or re-inset of<br>flaps in autologous reconstruction<br>or significant capsular revision<br>combined with soft tissue excision<br>in implant-based reconstruction) | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT®             | 19396  | Preparation of moulage for custom breast implant   | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| CPT®             | 21601  | Excision of chest wall tumor including rib(s)  | Prior Approval Required   |
| CPT®             | 21602  | Excision of chest wall tumor<br>involving rib(s), with plastic<br>reconstruction; without<br>mediastinal lymphadenectomy   | Prior Approval Required   |
| CPT <sup>®</sup> | 21603  | Excision of chest wall tumor<br>involving rib(s), with plastic<br>reconstruction; with mediastinal<br>lymphadenectomy  | Prior Approval Required   |
| HCPCS            | C1789  | Prosthesis, breast (implantable)   | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |

| Code<br>Type | Number | Brief Description  | Policy Instructions   |
|--------------|--------|--|---|
| HCPCS        | L8020  | Breast prosthesis, mastectomy form   | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| HCPCS        | L8030  | Breast prosthesis, silicone or equal, without integral adhesive                    | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| HCPCS        | L8031  | Breast prosthesis, silicone or equal with integral adhesive                        | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| HCPCS        | L8032  | Nipple prosthesis, prefabricated,<br>reusable, any material, any type,<br>each     | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| HCPCS        | L8033  | Nipple prosthesis, custom<br>fabricated, reusable, any material,<br>any type, each | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| HCPCS        | L8039  | Breast prosthesis, not otherwise specified   | Prior Approval Required   |
| HCPCS        | L8499  | Unlisted procedure for<br>miscellaneous prosthetic services                        | Prior Approval Required   |
| HCPCS        | L8699  | Prosthetic implant, not otherwise specified  | Prior Approval Required   |
| HCPCS        | Q4100  | Skin substitute, not otherwise specified   | Refer to Corporate<br>Bioengineered Skin Medical<br>Policy                    |
| HCPCS        | Q4107  | Graftjacket, per square<br>centimeter  | Refer to Corporate<br>Bioengineered Skin Medical<br>Policy                    |
| HCPCS        | Q4116  | Alloderm, per square centimeter  | Refer to Corporate<br>Bioengineered Skin Medical<br>Policy                    |
| HCPCS        | Q4122  | DermACELL, per sq cm   | Refer to Corporate<br>Bioengineered Skin Medical<br>Policy                    |
| HCPCS        | Q4128  | FlexHD, Allopatch HD, or Matrix<br>HD, per square centimeter                       | Refer to Corporate<br>Bioengineered Skin Medical<br>Policy                    |

| HCPCS<br>S2066<br>HCPCS<br>S2066<br>HCPCS<br>S2066<br>HCPCS<br>S2066<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS<br>HCPCS | onstruction with gluteal<br>forator (GAP) flap,<br>harvesting of the flap,<br>ular transfer, closure of<br>and shaping the flap<br>ast, unilateral<br>onstruction of a single<br>th "stacked" deep   | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
|---|--|---|
| breast wit<br>inferior er<br>(DIEP) flar  | -  |   |
| including<br>microvascu<br>donor site   | bigastric perforator<br>o(s) and/or gluteal<br>forator (GAP) flap(s),<br>harvesting of the flap(s),<br>ular transfer, closure of<br>e(s) and shaping the flap<br>ast, unilateral                     | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |
| HCPCS S2068 inferior en<br>flap, or su<br>epigastric<br>including<br>microvasc<br>donor site  | onstruction with deep<br>bigastric perforator (DIEP)<br>perficial inferior<br>artery (SIEA) flap,<br>harvesting of the flap,<br>ular transfer, closure of<br>and shaping the flap<br>ast, unilateral | Prior Approval Required<br>unless billed with a<br>diagnosis of breast cancer |